| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交全额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-12-19 | 002907 | 华森制药 | 13.57 | 14.80 | 200.84 机构专用 | | 华泰证券股份有限 | | | | | | | | | 公司宜都长江大道 | | | | | | | | | 证券营业部 | | 2025-12-19 | 002907 | 华森制药 | 13.57 | 14.74 | | 200.02 国金证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司上海浦东新区 | 公司宜都长江大道 | | | | | | | | 芳甸路证券营业部 | 证券营业部 | 12月19日，华森制药大宗交易成交29.54万股，成交额400.86万元，占当日总成交额的15.82%，成交价13.57元，较市场收盘 价15.21元折价10.78%。 ...

12月10日，华森制药大宗交易成交204.38万股，成交额2842.93万元，占当日总成交额的48.58%，成交 价13.91元，较市场收盘价15.5元折价10.26%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交会额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-12-10 | 002907 | 华森制药 | 13.91 | 152.50 | 2,121. 枫构专用 | | 华泰证券股份有限 | | | | | | | | | 公司宜都长江大道 | | | | | | | | | 证券营业部 | | 2025-12-10 | 002907 | 华森制药 | 13.91 | 23.10 | 321.32 机构专用 | | 华泰证券股份有限 | | | | | | | | | 公司宜都长江大道 | | | | | | | | | 证券营业部 | | 2025-12-10 | 002907 | 华森制药 | ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002907 证券简称：华森制药 公告编号：2025-087 重庆华森制药股份有限公司 关于控股股东及其一致行动人持股变动触及1%整数倍的公告 公司控股股东成都地方建筑机械化工程有限公司及其一致行动人游洪涛先生、王瑛女士、上海添橙投资 管理有限公司－添橙添利一号私募证券投资基金保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 ■ 重庆华森制药股份有限公司 董事会 2025年12月4日 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-087 重庆华森制药股份有限公司 关于控股股东及其一致行动人持股变动触及 1%整数 倍的公告 公司控股股东成都地方建筑机械化工程有限公司及其一致行动人游洪涛先生、 王瑛女士、上海添橙投资管理有限公司－添橙添利一号私募证券投资基金保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 公司于 2025 年 10 月 15 日披露了《关于公司控股股东一致行动人减持股份 预披露的公告》（公告编号：2025-078），游洪涛先生计划自预披露公告披露之 日起 15 个交易日后的 3 个月内（即 2025 年 11 月 6 日至 2026 年 2 月 5 日）通过 大宗交易方式减持公司股份合计不超过 6,649,826 股，占公司总股本的 1.59%。 添橙添利一号基金计划自预披露公告披露之日起 15 个交易日后的 3 个月内 （即 2025 年 11 月 6 日至 2026 年 2 月 5 日）通过集中竞价方式减持公司股份不 超过 4,175,900 股，占公司 ...

Core Insights - On December 1, Huason Pharmaceutical executed a block trade of 138,000 shares, with a transaction value of 2.012 million yuan, accounting for 6.72% of the total trading volume for the day. The transaction price was 14.58 yuan, representing a 10.5% discount compared to the market closing price of 16.29 yuan [1][2]. Summary by Categories - **Transaction Details** - The block trade involved 138,000 shares at a price of 14.58 yuan per share [1][2]. - The total transaction amount was 2.012 million yuan [1][2]. - The trade accounted for 6.72% of the total trading volume on that day [1]. - **Market Context** - The transaction price was at a 10.5% discount to the market closing price of 16.29 yuan [1].

Group 1 - On November 26, Huason Pharmaceutical executed a block trade of 136,000 shares, with a transaction value of 2.0033 million yuan, accounting for 3.68% of the total trading volume for the day [1][2] - The transaction price was 14.73 yuan, which represents a discount of 9.69% compared to the market closing price of 16.31 yuan [1][2]

Summary of Key Points Core Viewpoint - On November 24, Huason Pharmaceutical executed a block trade of 141,000 shares, amounting to 2.005 million yuan, which represented 5.33% of the total trading volume for the day. The transaction price was 14.22 yuan, reflecting an 11.62% discount compared to the market closing price of 16.09 yuan [1][2]. Group 1 - The block trade involved 141,000 shares of Huason Pharmaceutical [1]. - The total transaction value was 2.005 million yuan [1]. - The transaction price of 14.22 yuan was 11.62% lower than the market closing price of 16.09 yuan [1]. Group 2 - The trade was facilitated by Huatai Securities, with both the buying and selling parties being branches of the same company [2].

Core Insights - Huason Pharmaceutical's stock price increased by 2.09% on November 24, reaching 16.13 CNY per share, with a market capitalization of 6.736 billion CNY [1] - The company has seen a year-to-date stock price increase of 24.89%, but has experienced declines of 4.27% over the last five trading days, 5.06% over the last 20 days, and 12.50% over the last 60 days [2] - As of September 30, 2025, Huason Pharmaceutical reported a revenue of 626 million CNY, a year-on-year growth of 1.90%, while net profit attributable to shareholders decreased by 2.84% to 72.46 million CNY [3] Financial Performance - The company has made cumulative cash distributions of 192 million CNY since its A-share listing, with 100 million CNY distributed in the last three years [4] - As of September 30, 2025, the number of shareholders increased to 33,100, with an average of 9,063 circulating shares per shareholder, a decrease of 0.83% from the previous period [3] Business Overview - Huason Pharmaceutical, established on November 4, 1996, operates in the pharmaceutical industry, focusing on drug research, production, and sales [2] - The company's revenue composition includes 34.24% from otolaryngology drugs, 23.16% from digestive system drugs, 18.37% from psychiatric and neurological drugs, 15.02% from pharmaceutical commerce, and 7.76% from other fields [2] - The company is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine and related concepts such as innovative drugs and generic drugs [2]

Core Viewpoint - Huason Pharmaceutical announced the completion of domestic production registration for its product, Apselaziglan Tablets, with the National Medical Products Administration [2] Group 1 - The company has recently checked the National Medical Products Administration website and confirmed the registration of Apselaziglan Tablets [2] - The registration includes an application for the product's instructions to be adapted for elderly users [2] - The registration information has been publicly announced on the National Medical Products Administration website [2]

Group 1: Legal and Regulatory Issues - The National Healthcare Security Administration disclosed a bribery case involving Huang Mouyun, who was found guilty of bribing multiple healthcare professionals to increase sales of a traditional Chinese medicine product [1][2] - Huang Mouyun paid a total of 1.9263 million yuan in bribes to 15 doctors at a local hospital to secure sales, with the product achieving over 10 million yuan in sales since December 2018 [1][2] - The court ruled that Huang Mouyun's actions constituted bribery of non-state personnel, and he may receive a lighter sentence due to his confession [2] Group 2: Pharmaceutical Developments - Huason Pharmaceutical announced that its product, Amlodipine Besylate Tablets, has completed domestic production registration, aimed at enhancing market competitiveness amid an aging population [1] - Fosun Pharma's subsidiary has had its PD-1 monoclonal antibody, used for gastric cancer treatment, included in the breakthrough therapy designation, marking a significant advancement in cancer treatment options [3] - Tianyi Medical received a medical device registration certificate for its blood dialysis concentrate, which is intended for patients with acute and chronic renal failure [4] Group 3: Clinical Research and Results - Innovent Biologics reported that its drug, Ma Shidu Peptide, achieved a weight reduction of up to 20.1% in obese patients during a Phase III clinical trial, with significant improvements in various health metrics compared to the placebo group [5][6] - The trial involved 462 participants, with the Ma Shidu Peptide group showing an average weight loss of 18.55% after 60 weeks, while the placebo group only lost 3.02% [6] Group 4: Corporate Governance - Changchun High-tech announced a change in the shareholding structure of its controlling shareholder, which will not affect the company's operations or control [4][5] - Guangji Pharmaceutical's independent director, Guo Wei, resigned due to personal reasons, which may impact the board's composition and the presence of accounting professionals [8]